Bayer/Regeneron initiate second Phase III study of VEGF Trap-Eye

Bayer and Regeneron have dosed the first patient in Second Phase III Study (VIEW 2) for VEGF Trap-Eye in Wet Age-Related Macular Degeneration. The trial will enroll approximately 1,200 patients in up to 200 centers in Europe, Asia Pacific, Japan and Latin America.

Cytopia and Cancer Therapeutics collaborate on kinase inhibitors

Cytopia and Cancer Therapeutics CRC have initiated a collaboration t aimed at leveraging Cytopia’s early stage drug discovery pipeline of kinase inhibitors.

Phase I initiated for EntreMeds Aurora Kinase inhibitor ENMD-2076

The Dana-Farber Cancer Inst has initiated Phase I trials of Entremed’s Aurora A kinase inhibitor ENMD-2076 in advanced cancer patients.